Cat. No.: HY-157122

VJDT

4 Cited Publications

Customer Review

Based on 4 publication(s) in Google Scholar

VJDT is a TREM1 inhibitor that can effectively block TREM1 signaling. VJDT inhibits tumor cell proliferation and migration and induces cell cycle arrest. VJDT has immunomodulatory and antitumor activities, and can be used for the research of tumors such as melanoma.

For research use only. We do not sell to patients.

Purity: 99.68%
CAS No.: 2765319-65-9
Formula: C₂₃H₁₇N₃O₃
Molecular Weight:383.40

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

VJDT Chemical Structure

CAS No.: 2765319-65-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (4)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

IL-6

TREM-1

All TREM receptor Isoforms :

All Akt Isoforms :

All PI3K Isoforms :

All Interleukin Related Isoforms :

All NF-κB Isoforms :

In Vitro

VJDT (10-50 μM) induces cell cycle arrest in HepG2 cells and inhibits cell proliferation and migration in B16F10 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

VJDT (20 mg/kg; intraperitoneal injection; every other day; day 30 to 48) exhibits antitumor activity in mice bearing patient-derived melanoma xenografts^[1].
VJDT (20 mg/kg; intraperitoneal injection; every other day; day 8 to 20) in Trem1^+/+ mice, when used in combination with anti-PD-1 antibody, exerts a potent antitumor effect^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

NSG mice treated patient-derived melanoma xenograft TM0094^[1]
Dosage:

20 mg/kg
Administration:

Intraperitoneal injection, every other day from day 30 to day 48
Result:

Significantly suppressed PDX tumor growth.
Downregulated key oncogenic pathways (PI3K-Akt, focal adhesion, IL-18 signaling).
Reduced expression of TREM1 and its target genes (NFKB1, CCL20, IL6, CXCL8).

Animal Model:

C57BL/6J mice treated B16F10 cells^[1]
Dosage:

20 mg/kg
Administration:

Intraperitoneal injection, every other day from day 8 to day 20
Result:

Completely inhibited tumor growth.
Significantly reduced MDSC frequency, expanded activated CD8⁺ T cells, and increased IFN-γ-producing CD8⁺ T cells compared to monotherapies.

Chemical Information

CAS No. 2765319-65-9
Appearance Solid
Molecular Weight 383.40
Formula C₂₃H₁₇N₃O₃
Color White to off-white
SMILES

O=C(N1CC2=CC=CC=C2)[C@@H]3C=C(C#N)[C@H]1C(C(N4C5=CC=CC=C5)=O)C3C4=O
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (4)

All

Sort by:

Journal Impact Factor

Liver Int

TREM1+ Neutrophils Determine Immunosuppressive Microenvironment and Immunotherapy Response in Hepatocellular Carcinoma. [Abstract]

2026 Jul;46(7):e70726. PMID: 42244441
Autoimmunity

Aberrant expression of triggering receptor expressed on myeloid cell-1 is involved in the immunopathological mechanism of myasthenia gravis. [Abstract]

2026 Dec 31;59(1):2620252. PMID: 41588655
Cell Biochem Biophys

Pharmacological Inhibition or Silencing of TREM1 Restrains HCC Cell Metastasis by Inactivating TLR/PI3K/AKT Signaling. [Abstract]

2024 Sep;82(3):2673-2685. PMID: 38954352
bioRxiv

Age-associated modulation of TREM1/2- expressing macrophages promotes melanoma progression and metastasis. [Abstract]

2024 Nov 21:2024.11.20.624563. PMID: 39605514

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (260.82 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6082 mL

13.0412 mL

26.0824 mL

5 mM

0.5216 mL

2.6082 mL

5.2165 mL

10 mM

0.2608 mL

1.3041 mL

2.6082 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (13.04 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (13.04 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ajith A,et al. Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti-PD-1 resistance. J Clin Invest. 2023 Nov 1;133(21):e167951. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6082 mL	13.0412 mL	26.0824 mL	65.2061 mL
	5 mM	0.5216 mL	2.6082 mL	5.2165 mL	13.0412 mL
	10 mM	0.2608 mL	1.3041 mL	2.6082 mL	6.5206 mL
	15 mM	0.1739 mL	0.8694 mL	1.7388 mL	4.3471 mL
	20 mM	0.1304 mL	0.6521 mL	1.3041 mL	3.2603 mL
	25 mM	0.1043 mL	0.5216 mL	1.0433 mL	2.6082 mL
	30 mM	0.0869 mL	0.4347 mL	0.8694 mL	2.1735 mL
	40 mM	0.0652 mL	0.3260 mL	0.6521 mL	1.6302 mL
	50 mM	0.0522 mL	0.2608 mL	0.5216 mL	1.3041 mL
	60 mM	0.0435 mL	0.2174 mL	0.4347 mL	1.0868 mL
	80 mM	0.0326 mL	0.1630 mL	0.3260 mL	0.8151 mL
	100 mM	0.0261 mL	0.1304 mL	0.2608 mL	0.6521 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

VJDT

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Cytokine Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) VJDT

All TREM receptor Isoforms

All Akt Isoforms

All PI3K Isoforms

All Interleukin Related Isoforms

All NF-κB Isoforms

Biological Activity

Chemical Information

Publications (4)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

VJDT Related Classifications

HY-157122 Related Classifications